Past two years Past Year Past 30 Days
Abstract Views 217 84 2
Full Text Views 3 0 0
PDF Downloads 0 0 0
 
 
 
 
 
 
 
 
 
 
 

Single-Dose Chloroquine Therapy for Plasmodium falciparum in Children in Togo, West Africa

Joel G. BremanMalaria Branch

Search for other papers by Joel G. Breman in
Current site
Google Scholar
PubMed
Close
,
Anani GayiborNational Malaria Service

Search for other papers by Anani Gayibor in
Current site
Google Scholar
PubMed
Close
,
Jacquelin M. RobertsDivision of Parasitic Diseases, Center for lnfectious Diseases

Search for other papers by Jacquelin M. Roberts in
Current site
Google Scholar
PubMed
Close
,
John D. SextonMalaria Branch

Search for other papers by John D. Sexton in
Current site
Google Scholar
PubMed
Close
,
Kossi AgboParasitology Department, School of Medicine, University of Benin, Lomé, Togo

Search for other papers by Kossi Agbo in
Current site
Google Scholar
PubMed
Close
,
Kirk D. MillerMalaria Branch

Search for other papers by Kirk D. Miller in
Current site
Google Scholar
PubMed
Close
,
Tchasseu KarsaEpidemiology Division and Combatting Childhood Communicable Diseases Program, Ministry of Health, Social Affairs and Women's Status

Search for other papers by Tchasseu Karsa in
Current site
Google Scholar
PubMed
Close
, and
Kevin Murphy

Search for other papers by Kevin Murphy in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

Chloroquine, in a single dose of 10 mg of base/kg, was given orally to Togolese children <5 years of age as primary therapy for Plasmodium falciparum malaria. A simplified World Health Organization in vivo method was used, as was a sequential analysis procedure for determining if the drug trial was a success or failure. A total of 178 children in 3 regions were treated; 174 (98%) responded successfully, which required a ≥75% reduction in parasites by day 2 and elimination of parasites by day 7. All 4 failures had low blood levels of chloroquine and desethylchloroquine at day 7. A single dose of chloroquine for treating malaria can be considered for those areas of Africa where the efficacy of such therapy is documented, and where an antimalarial drug sensitivity monitoring system is operating.

Save